NewAmsterdam Pharma (NAMS) EPS (Basic) (2023 - 2026)

NewAmsterdam Pharma has reported EPS (Basic) for 4 years, with the latest figure at -$0.4 in Q1 2026.

• Quarterly EPS (Basic) fell 16.92% year-over-year to -$0.4 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.75 (down 8.33% YoY) and the FY2025 annual result came in at -$1.28, up 50.12% from the prior year.
• EPS (Basic) advanced to -$0.4 in Q1 2026 per NAMS's latest filing, from -$0.63 in the prior quarter.
• Over five years, EPS (Basic) peaked at -$0.15 in Q2 2025 and troughed at -$1.06 in Q1 2024.
• A 4-year average of -$0.54 and a median of -$0.54 in 2023 frame the typical range for EPS (Basic).
• The sharpest annual moves came in 2024 and 2025: EPS (Basic) soared 69.26% in 2024, then sank 244.41% in 2025.
• Over 4 years, EPS (Basic) stood at -$0.6 in 2023, then tumbled by 62.25% to -$0.98 in 2024, then jumped by 35.24% to -$0.63 in 2025, then surged by 37.09% to -$0.4 in 2026.
• According to Business Quant data, EPS (Basic) over the past three periods registered -$0.4, -$0.63, and -$0.61 for Q1 2026, Q4 2025, and Q3 2025 respectively.